Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)

BACKGROUND: A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label randomized phase II trial, was designed to assess the benefit of main...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hisashi, Hasegawa, Yukihiro, Fujita, Yuka, Nakamura, Atsushi, Kikuchi, Eiki, Kawai, Yasutaka, Harada, Toshiyuki, Watanabe, Naomi, Yokouchi, Hiroshi, Usui, Kazuhiro, Saito, Ryota, Watanabe, Hiroshi, Masuda, Tomomi, Fukuhara, Tatsuro, Kudo, Keita, Honda, Ryoichi, Oizimi, Satoshi, Maemondo, Makoto, Inoue, Akira, Morikawa, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287008/
https://www.ncbi.nlm.nih.gov/pubmed/34076966
http://dx.doi.org/10.1111/1759-7714.14048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287008/
https://www.ncbi.nlm.nih.gov/pubmed/34076966
http://dx.doi.org/10.1111/1759-7714.14048

Ejemplares similares